Page 472 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
relevant to KQ4 (continued)
Author, Year Study name Comparison Study Sample Inclusion criteria Population description: Quality
[Pubmed ID] /Database duration size (total) Age Comments
PSA (ng/mL)
Study design Tumor grade
Stage
Rice 232 Center for WW (with or Median 770 12,081 patient records from the Mean age at survey: WW C
2011 Prostate without 6.4 yr (all CPDR databse of men without secondary treatment,
21872499 Disease secondary groups) diagnosed with prostate cancer 75.7 yr; WW with secondary Significant
Research treatment) vs. from 1989 to 2009. Of these treatment, 74.5 yr; EBRT, 74.1 difference
Retrospective (CPDR) EBRT vs. RP Mean: 3650 were found to be ≥70 yr; RP, 72.2 yr (P<0.001 in followup
cohort database WW years old. between groups) time
without Patient who met the D’Amico between
secondary criteri for low-risk disease (stage PSA (ng/mL): WW without groups;
treatment, T1-2a, Gleason score ≤6, and secondary treatment, 4.7; WW self-
5.3 yr; PSA <10 ng/ml) and were with secondary treatment, 5.6; selection
WW with managed with primary RP, EBRT, 6.0; RP, 5.3 (P<0.001 bias likely;
secondary EBRT, or WW were selected for between groups) secondary
treatment, analysis. treatment in
8.4 yr; WW was defined as patient who Gleason score: NR WW group
EBRT, 7.0 declared the intent to pursue not properly
yr; RP. 7.2 such pathway and not Stage (P=0.32 between accounted
yr undergone definitive treatment groups): for in
(P<0.0001 within 9 months of diagnosis; T1: WW without secondary analyses.
between this group was further stratified treatment, 66%; WW with
groups) into patients who subsequently secondary treatment, 61%;
received or did not receive EBRT, 60%; RP, 57%
secondary treatment. T2a: WW without secondary
Exclusion: any of the risk treatment, 34%; WW with
stratification criteria were secondary treatment, 39%;
missing or <6 months followup EBRT, 40%; RP, 43%
since primary treatment.

C-154